2027 ICD-10-CM Diagnosis Code C80.2Malignant neoplasm associated with transplanted organ
ICD-10-CM Codes›C00–D49›C76-C80›C80
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 23
- Not a Principal Diagnosis
- Chronic Condition
C80.2 is a billable ICD-10-CM diagnosis code for malignant neoplasm associated with transplanted organ. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 826 through 830, 843 through 845. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 19 closely related codes. The code is not accepted as a principal diagnosis by the Medicare Code Editor. Coders also document this condition as donor derived melanoma. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Malignant neoplasm, unspecified.
For Medicare Advantage risk adjustment, C80.2 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for C80.2.
Medicare Risk Adjustment (HCC)Billing
C80.2 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Donor derived melanoma
- Neoplasm following transplantation of kidney
- Post-transplant neoplasia
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C80.2: its own notes plus those printed at C80 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Code First
The underlying condition named in the note is sequenced before this code.
- complication of transplanted organ (T86.-)
Use Additional Code
Add a second code, after this one, to fully describe the condition.
- code to identify the specific malignancy
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C80.2, its category, or a range that includes it.
Use Additional Code 1
These codes say to use an additional code from the note, and C80.2 is one of the codes named.
- T86 Complications of transplanted organs and tissuemalignancy associated with organ transplant (C80.2)
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Transplant-Related Malignant Neoplasm
a malignant neoplasm that arises in a patient with a history of organ transplantation.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| associated with transplanted organ | C80.2 | – | – | – | – | – |
Patient EducationClinical
Cancer
Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should.
The full article covers:
- What is cancer?
- What are the types of cancer?
- How does cancer develop?
- What are the symptoms of cancer?
- How is cancer diagnosed?
- What are the treatments for cancer?
- Can cancer be prevented?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C80.2 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C80.2Overview
What is the ICD-10 code for malignant neoplasm associated with transplanted organ?
The ICD-10-CM code for malignant neoplasm associated with transplanted organ is C80.2 (sometimes written as C802). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C80.2 (Malignant neoplasm without specification of site) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm associated with transplanted organ on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C80.2 group to?
On inpatient claims, malignant neoplasm associated with transplanted organ maps to MS-DRG 844, 827, 829, 843, 828, 826, 830, 845, with relative weights from 0.8443 to 4.7560 depending on complications. Higher weights mean higher Medicare reimbursement.
Is C80.2 a CC or MCC?
CMS lists C80.2 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 19 closely related codes in its exclusion list.
Can C80.2 be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because malignant neoplasm associated with transplanted organ describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What HCC is C80.2?
C80.2 (malignant neoplasm associated with transplanted organ) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C80.2 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C80.2 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.
